Sara Valdeolivas

A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease

José Luis López-Sendón, Juan García Caldentey, Patricia Trigo Cubillo et al. · Journal of Neurology · 2016 · 157 citations

Life Sciences, Neurology, Neuroscience +9

Neuroprotective Properties of Cannabigerol in Huntington's Disease: Studies in R6/2 Mice and 3-Nitropropionate-lesioned Mice

Sara Valdeolivas, Carmen Navarrete, Irene Cantarero et al. · Neurotherapeutics · 2014 · 136 citations · Full text

Medicine, Neuroscience, Pharmacology +15

Sativex-like Combination of Phytocannabinoids is Neuroprotective in Malonate-Lesioned Rats, an Inflammatory Model of Huntington’s Disease: Role of CB₁ and CB₂ Receptors

Sara Valdeolivas, Valentina Satta, Roger G. Pertwee et al. · ACS Chemical Neuroscience · 2012 · 90 citations

Medicine, Neuroscience, Pharmacology +17

The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG

Sara Valdeolivas, M. Ruth Pazos, Tiziana Bisogno et al. · Cell Death and Disease · 2013 · 85 citations · Full text

Medicine, Neuroscience, Pharmacology +17

Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington’s Disease

Sara Valdeolivas, Onintza Sagredo, Mercedes Delgado et al. · International Journal of Molecular Sciences · 2017 · 50 citations · Full text

Medicine, Neuroscience, Pharmacology +17